KAS
ARQT icon

Kestra Advisory Services’s Arcutis Biotherapeutics ARQT Stock Holding History

Kestra Advisory Services’s Portfolio ARQT Stock Details ARQT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$206K Sell
7,850
-1,036
-12% -$24.1K ﹤0.01% 3087
2026
Q1 		$209K Sell
8,886
-560
-6% -$14.3K ﹤0.01% 2918
2025
Q4 		$274K Sell
9,446
-674
-7% -$17.3K ﹤0.01% 2616
2025
Q3 		$191K Sell
10,120
-1,430
-12% -$22.6K ﹤0.01% 2752
2025
Q2 		$162K Buy
+11,550
New +$162K ﹤0.01% 2686

Other funds holding ARQT

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Kestra Advisory Services's ARQT Position: Q2 2026 in Review

Kestra Advisory Services reduced its Arcutis Biotherapeutics (ARQT) stake by 12% in Q2 2026, selling an estimated $24.1K and leaving 7,850 shares worth $206K. The position accounts for ﹤0.01% of the portfolio, ranked #3087.

Kestra Advisory Services first reported a position in ARQT in Q2 2025 and has held it in 5 quarters since. The position peaked at $274K in Q4 2025. 272 funds tracked by Wall St. Rank hold ARQT as of Q2 2026.

  • Kestra Advisory Services held 7,850 shares of Arcutis Biotherapeutics worth $206K as of Q2 2026.
  • Kestra Advisory Services sold 1,036 Arcutis Biotherapeutics shares in Q2 2026, an estimated $24.1K.
  • Arcutis Biotherapeutics made up ﹤0.01% of Kestra Advisory Services's portfolio in Q2 2026, its #3087 holding.
  • Kestra Advisory Services first reported a position in Arcutis Biotherapeutics in Q2 2025 and has held it in 5 quarters since.
  • Kestra Advisory Services's Arcutis Biotherapeutics position peaked at $274K in Q4 2025.
  • 272 funds tracked by Wall St. Rank held Arcutis Biotherapeutics as of Q2 2026.

Based on Kestra Advisory Services's 13F filing for Q2 2026, filed 28 Jul 2026.